CLINICAL TRIALS PROFILE FOR DILANTIN-30

All Clinical Trials for Dilantin-30

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00005951 ↗	Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma	Completed	National Cancer Institute (NCI)	Phase 1	2000-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
NCT00005951 ↗	Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma	Completed	Duke University	Phase 1	2000-08-01	RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I trial to study the effectiveness of irinotecan plus temozolomide in treating patients who have recurrent primary malignant glioma.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	Center for Cell and Gene Therapy, Baylor College of Medicine	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	Texas Children's Hospital	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	The Methodist Hospital Research Institute	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	The Methodist Hospital System	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.
NCT00040469 ↗	Bone Marrow Transplant From Related Donor for Patients With High Risk Hemoglobinopathies	Terminated	Baylor College of Medicine	Phase 2	2000-08-01	The major goal of this study is to determine the risks and benefits of bone marrow transplants in patients with severe thalassemia or sickle cell disease. Participation in this project will be for two years.

Clinical Trial Conditions for Dilantin-30

Condition Name

Condition Name for Dilantin-30
Intervention	Trials
Leukemia	3
Traumatic Brain Injury	3
Gliosarcoma	3
Healthy	3

Condition MeSH

Condition MeSH for Dilantin-30
Intervention	Trials
Seizures	5
Glioma	4
Brain Injuries	3
Gliosarcoma	3

Clinical Trial Locations for Dilantin-30

Trials by Country

Trials by Country for Dilantin-30
Location	Trials
United States	22
Korea, Republic of	1
Canada	1
Singapore	1

Trials by US State

Trials by US State for Dilantin-30
Location	Trials
Ohio	3
Texas	3
North Carolina	3
Pennsylvania	2
New York	2

Clinical Trial Progress for Dilantin-30

Clinical Trial Phase

Clinical Trial Phase for Dilantin-30
Clinical Trial Phase	Trials
Phase 4	6
Phase 3	2
Phase 2	4

Clinical Trial Status

Clinical Trial Status for Dilantin-30
Clinical Trial Phase	Trials
Completed	13
Terminated	8
Recruiting	1

Clinical Trial Sponsors for Dilantin-30

Sponsor Name

Sponsor Name for Dilantin-30
Sponsor	Trials
Baylor College of Medicine	3
National Cancer Institute (NCI)	3
Duke University	3

Sponsor Type

Sponsor Type for Dilantin-30
Sponsor	Trials
Other	35
Industry	10
NIH	4